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Abstract
Background: Serum bilirubin may have potent antioxidant and cytoprotective effects. Serum bilirubin levels are inversely
associated with several cardiovascular and metabolic endpoints, but their association with nonalcoholic fatty liver disease
(NAFLD) has not been investigated except for a single cross-sectional study in a pediatric population. We assessed the
prospective association between serum bilirubin concentrations (total, direct, and indirect) and the risk for NAFLD.
Methods and Findings: We performed a cohort study in 5,900 Korean men, 30 to 59 years of age, with no evidence of liver
disease and no major risk factors for liver disease at baseline. Study participants were followed in annual or biennial health
examinations between 2002 and 2009. The presence of fatty liver was determined at each visit by ultrasonography. We
observed 1,938 incident cases of NAFLD during 28,101.8 person-years of follow-up. Increasing levels of serum direct
bilirubin were progressively associated with a decreasing incidence of NAFLD. In age-adjusted models, the hazard ratio for
NAFLD comparing the highest to the lowest quartile of serum direct bilirubin levels was 0.61 (95% CI 0.54–0.68). The
association persisted after adjusting for multiple metabolic parameters (hazard ratio comparing the highest to the lowest
quartile 0.86, 95% CI 0.76–0.98; P trend=0.039). Neither serum total nor indirect bilirubin levels were significantly associated
with the incidence of NAFLD.
Conclusions: In this large prospective study, higher serum direct bilirubin levels were significantly associated with a lower
risk of developing NAFLD, even adjusting for a variety of metabolic parameters. Further research is needed to elucidate the
mechanisms underlying this association and to establish the role of serum direct bilirubin as a marker for NAFLD risk.
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Introduction
Nonalcoholic fatty liver disease (NAFLD) encompasses a
spectrum of liver disorders characterized by steatosis with varying
degrees of inflammatory activity, necrosis and fibrosis [1,2].
NAFLD may progress to cirrhosis or hepatocellular carcinoma
and is associated with increased risk of cardiovascular morbidity
and mortality [3,4]. NAFLD is closely related to obesity,
dyslipidemia, insulin resistance, and type 2 diabetes, and it is
considered a manifestation of the metabolic syndrome [5,6,7].
While _ENREF_11NAFLD is the most prevalent form of liver
disease [8,9], its pathophysiology is still not fully understood [10]
and there is substantial interest in identifying novel determinants
of NAFLD incidence.
Bilirubin is a product of heme catabolism [11] that may have
potent antioxidant and cytoprotective properties [11,12]. A
growing body of literature shows that higher bilirubin levels are
inversely associated with HOMA-IR and insulin levels [13] and
with the prevalence of cardiovascular disease [14,15,16,17,18] and
diabetes [19]. Furthermore, an increased expression of heme
oxygenase, the enzyme that catalyzes the breakdown of hemoglo-
bin into bilirubin, is associated with reduced adiposity and
improved insulin sensitivity in animal models [20,21]. Only one
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e37241cross-sectional study, conducted among obese children, has
evaluated the association between serum bilirubin and NAFLD
[22]. In this study, serum total bilirubin levels were lower in
participants with NAFLD compared to those without NAFLD. No
information is available on the association of serum bilirubin levels
and NAFLD in adults. The goal of our study was thus to evaluate
the prospective association between bilirubin concentrations (total,
direct, and indirect) and the risk of NAFLD.
Methods
Study Population
The study population consisted of male workers from one of the
largest semiconductor manufacturing companies in Korea and its
13 affiliates [23,24]. In Korea, the Industrial Safety and Health
Law requires that employees participate in annual or biennial
health examinations. Study participants were all male workers 30
Table 1. Baseline characteristics of study participants by quartile of serum direct bilirubin (N=5,900).
Overall Direct bilirubin P value trend
Quartile 1 Quartile 2 Quartile 3 Quartile 4
Number 5900 2196 1,319 924 1461
Direct bilirubin, mg/dL
* 0.44 (0.21) 0.25 (0.07) 0.4 (0) 0.5 (0) 0.73 (0.16)
Range 0–1.7 0– 0.4– 0.5– 0.6–1.7
Age, years
* 36.8 (4.9) 37.0 (5.1) 36.9 (4.9) 36.6 (4.8) 36.5 (4.7) 0.004
BMI, kg/m
2* 22.9 (2.4) 23.2 (2.4) 22.9 (2.4) 22.7 (2.4) 22.4 (2.3) ,0.001
Current smoker, % 43.4 48.2 42.6 42.9 37.0 ,0.001
Alcohol intake, %
{ 27.5 27.3 27.1 30.8 26.2 0.95
Regular exercise, %
1 51.4 49.8 50.6 54.3 52.8 0.03
Hypertension, % 12.1 12.3 13.0 13.1 10.6 0.20
Metabolic syndrome, % 4.8 6.8 4.6 4.6 2.2 ,0.001
Diabetes mellitus, % 0.6 0.5 0.7 0.7 0.8 0.26
Cardiovascular dis., % 0.1 0.1 0.1 0.2 0.1 0.82
Malignancy, % 0.2 0.1 0.3 0.2 0.3 0.44
Lipid lowering agent, % 0.4 0.5 0.5 0.3 0.2 0.14
Hemoglobin, g/dL 15.0 (0.9) 14.9 (0.9) 15.0 (0.8) 15.1 (0.8) 15.2 (0.8) ,0.001
Leukocyte, 610
3/mL 5.8 (1.4) 6.0 (1.4) 5.8 (1.4) 5.7 (1.4) 5.5 (1.3) ,0.001
Systolic BP, mmHg
* 114.1 (12.2) 114.1 (12.2) 114.3 (12.0) 114.3 (12.3) 113.7 (12.3) 0.38
Diastolic BP, mmHg
* 73.8 (9.7) 73.7 (9.7) 74.3 (9.6) 73.8 (10.0) 73.6 (9.6) 0.62
Glucose, mg/dL
* 90.2 (11.6) 91.7 (10.4) 90.3 (11.4) 90.0 (10.9) 88.1 (13.4) ,0.001
Uric acid, mg/dL
* 5.84 (1.07) 5.83 (1.07) 5.85 (1.07) 5.86 (1.05) 5.83 (1.09) 0.95
Tot. cholesterol, mg/dL
* 194.7 (32.2) 201.3 (32.4) 196.2 (32.5) 191.2 (31.3) 185.7 (29.6) ,0.001
LDL-C, mg/dL
* 116.3 (27.7) 120.8 (27.7) 117.4 (27.7) 114.0 (27.6) 110.0 (26.5) ,0.001
HDL-C, mg/dL
* 53.4 (11.6) 51.1 (11.0) 53.2 (11.8) 54.0 (11.1) 56.8 (11.7) ,0.001
Triglycerides, mg/dL
{ 109.0 (82.0–150.0) 122.0 (90.0–166.0) 113.0 (84.0–153.0) 104.0 (80.0–142.0) 96.0 (74.0–128.0) ,0.001
Total bilirubin, mg/dL 1.18 (0.48) 0.80 (0.20) 1.07 (0.18) 1.28 (0.21) 1.76 (0.48) ,0.001
Indirect bilirubin, mg/dL 0.73 (0.31) 0.55 (0.18) 0.67 (0.18) 0.78 (0.21) 1.03 (0.37) ,0.001
Albumin, g/dL 4.43 (0.19) 4.43 (0.19) 4.43 (0.19) 4.43 (0.19) 4.43 (0.19) 0.59
ALT, IU/L
{ 20.0 (16.0–25.0) 21.0 (17.0–27.0) 21.0 (17.0–26.0) 19.0 (16.0–25.0) 19.0 (16.0–23.0) ,0.001
AST, IU/L
{ 21.0 (19.0–24.0) 21.0 (19.0–24.0) 21.0 (19.0–24.0) 21.0 (19.0–24.0) 21.0 (18.0–24.0) 0.01
GGT, IU/L
{ 20.0 (15.0–27.0) 21.0 (16.0–28.0) 20.0 (15.0–28.0) 20.0 (15.0–26.0) 19.0 (15.0–25.0) ,0.001
ALP, IU/L{ 54.0 (47.0–63.0) 55.0 (47.0–64.0) 54.0 (47.0–63.0) 53.0 (47.0–62.0) 53.0 (46.0–62.0) ,0.001
hsCRP, mg/L
{ 0.40 (0.20–0.80) 0.50 (0.20–1.00) 0.40 (0.20–0.80) 0.40 (0.20–0.70) 0.30 (0.20–0.60) ,0.001
Insulin, mU/dL{ 6.33 (5.10–8.20) 6.89 (5.36–8.99) 6.41 (5.17–8.20) 6.03 (4.92–7.60) 5.88 (4.83–7.46) ,0.001
HOMA2-IR{ 0.82 (0.66–1.07) 0.90 (0.70–1.17) 0.83 (0.67–1.07) 0.78 (0.64–1.00) 0.76 (0.63–0.96) ,0.001
Data are.
*means (standard deviation),
{medians (interquartile range), or percentages.
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; BP, blood pressure; GGT, gamma-glutamyltranspeptidase; ALP,
alkaline phosphatase; HDL-C, high-density lipoprotein-cholesterol; hsCRP, high sensitivity C-reactive protein; HOMA2-IR, homeostasis model assessment 2 of insulin
resistance; LDL-C: low-density lipoprotein-cholesterol.
{$20 g of ethanol per day.
1$1 time/week.
doi:10.1371/journal.pone.0037241.t001
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companies who participated in a comprehensive health examina-
tion at the Kangbuk Samsung Hospital in Seoul, Korea in 2002
(N=15,347). For this analysis, we excluded 5053 participants with
ultrasonographic evidence of fatty liver at baseline, 585 partic-
ipants with missing data on bilirubin or other covariates at
baseline, and 1611 participants not attending any follow-up visit
after the baseline visit. The sample size for the eligible population
was 8,871.
This study was approved by the Institutional Review Board of
the Kangbuk Samsung Hospital. The informed consent require-
ment was exempted by the Institutional Review Board because
researchers only accessed retrospectively a de-identified database
for analysis purposes.
Measurements
Baseline and follow-up examinations were conducted at the
Kangbuk Samsung Hospital Health Screening Center. Study
participants were examined annually or biennially until December
2009. Baseline and follow-up health examinations collected data
on medical history, medication use, health-related behaviors,
physical measurements, and serum biochemical measurements
[23]. Questions pertaining to alcohol intake included weekly
frequency of alcohol consumption and usual daily amount of
consumption. Questionnaire data were also used to identify
current smokers and to assess the weekly frequency of moderate-
or vigorous-intensity physical activity. Body weight was measured
with light clothing and without shoes to the nearest 0.1 kilogram
using a digital scale. Height was measured to the nearest 0.1
centimeter. Body mass index was calculated as weight in kilograms
divided by height in meters squared. Trained nurses measured
sitting blood pressure with a mercury sphygmomanometer.
Blood specimens were sampled from the antecubital vein after
more than 12 hours of fasting. Serum levels of glucose, uric acid,
total cholesterol, triglycerides, low-density lipoprotein (LDL)
cholesterol, high-density lipoprotein (HDL) cholesterol, gamma-
glutamyltransferase (GGT), alanine aminotransferase (ALT),
aspartate aminotransferase (AST), alkaline phosphatase and total
bilirubin and direct bilirubin were measured using Bayer Reagent
Packs on an automated chemistry analyzer (Advia 1650
TM
Autoanalyzer; Bayer Diagnostics, Leverkusen, Germany). Serum
total and direct bilirubin were measured with the vanadate
oxidation method. The total coefficients of variation for total
bilirubin determinations were ,2.1% and ,1.6% for low-level
and high-level quality control samples during the study period,
respectively. The total coefficients of variation for direct bilirubin
determinations were ,5.9% and ,3.3% for low-level and high-
level quality control samples, respectively. Insulin was measured
using an immunoradiometric assay (Biosource, Nivelles, Belgium).
Insulin resistance was assessed with the homeostasis model
assessment 2 of insulin resistance (HOMA2-IR) [26]. High
sensitivity-C reactive protein (hsCRP) was analyzed by particle-
enhanced immunonephelometry with the BNII
TM System (Dade
Behring, Marburg, Germany) using a lower detection limit of
0.175 mg/L. The clinical laboratory has been accredited and
participates annually in inspections and surveys by the Korean
Association of Quality Assurance for Clinical Laboratories.
Abdominal ultrasounds were performed with a 3.5-MHz
transducer (Logic Q700 MR, GE, Milwaukee, WI) by 12
experienced radiologists who were unaware of the aims of the
study and blinded to laboratory values. Images were captured in a
standard fashion with the patient in the supine position with the
right arm raised above the head [24]. An ultrasonographic
diagnosis of fatty liver (USFL) was defined as the presence of a
diffuse increase of fine echoes in the liver parenchyma compared
with the kidney or spleen parenchyma [27]. Diagnoses were made
by the radiologists using liver images. The study outcome was the
development of NAFLD, defined as the presence of new cases of
USFL appearing in this cohort free of liver disease or traditional
risk factors for liver disease at baseline.
Figure 1. Cumulative incidence of non-alcoholic fatty liver
disease by quartile of serum direct bilirubin concentration.
doi:10.1371/journal.pone.0037241.g001
Figure 2. Multivariable-adjusted hazard ratio (95% confidence
interval) for non-alcoholic fatty liver disease by concentration
of serum direct bilirubin. Risk trends were estimated using restricted
quadratic splines with knots at the 5
th,5 0
th, and 95
th percentiles of the
direct bilirubin distribution (the reference value with hazard ratio=1
was set at the 50
th percentile). The horizontal dotted line indicates a
hazard ratio of 1. The spline regression model was adjusted for age,
BMI, smoking, alcohol intake, exercise, HDL cholesterol, triglycerides,
glucose, insulin, and uric acid. The histogram represents the frequency
distribution of direct bilirubin concentrations in the study population.
doi:10.1371/journal.pone.0037241.g002
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Cholesterol Education Program Adult Treatment Panel III [28]
as the presence of three or more of the following five
abnormalities: 1) abdominal obesity; 2) fasting blood glucose
$110 mg/dL; 3) fasting serum triglycerides $150 mg/dL (to
convert to mmol/L, multiply by 0.01129); 4) HDL cholesterol
,40 mg/dL (to convert to mmol/L, multiply by 0.02586); and 5)
blood pressure $130/85 mm Hg. Because waist circumference
measurements were not available for all participants, we substi-
tuted abdominal obesity with overall adiposity as a BMI of
$25 kg/m
2, which was proposed as a cut-off for diagnosis of
obesity in Asian populations [29]. Diabetes mellitus was defined by
a self-reported physician diagnosis, self-reported medical therapy
for diabetes mellitus or fasting serum blood glucose greater than
126 mg/dL. Cardiovascular disease (any type of heart disease or
stroke) and malignancy was defined by a self-reported physician
diagnosis. Hypertension was defined as use of antihypertensive
medication, self-reported history or blood pressure $140/90 mm
Hg.
Statistical Analyses
Since NAFLD is a diagnosis of exclusion, the primary analyses
were based on the subset of study participants who did not have
any evidence of liver disease or any risk factors for liver disease at
baseline. For the primary analyses, we further excluded 9
participants taking medications for hepatitis; 457 participants with
positive serologic markers for hepatitis B or C virus; 140
participants with ultrasonographic findings of chronic liver disease,
liver cirrhosis, cholelithiasis, or abnormal dilatation of the biliary
tree; 6 participants who, in the past year, had taken medications
that may induce NAFLD (e.g., steroids, immune suppressants,
anticonvulsants, and tetracyclines); 1473 participants reporting an
alcohol intake $20 g/day [2,25]; 1082 participants with elevated
alanine aminotransferase (ALT) levels (.35 U/L); and 271
participants with elevated aspartate aminotransferase (AST) levels
(.40 U/L). Because some individuals met more than one
exclusion criterion, the total number of men eligible for the study
at baseline was 5900. As sensitivity analyses, we also performed
analyses in the overall study population (N=8,871), adjusted for
the presence of liver disease or of risk factors for liver disease at
baseline.
One-way ANOVA and x
2-tests were used to compare the
characteristics of study participants at baseline by quartiles of
serum direct (,0.4, 0.4–,0.5, 0.5–,0.6, and $0.6 mg/dL),
indirect (,0.6, 0.6–,0.7, 0.7–,0.9, $0.9 mg/dL), or total
bilirubin (,1.0, 1.0–,1.2, 1.2–,1.5, and $1.5 mg/dL). The
distribution of continuous variables was evaluated and appropriate
transformations were done in the analysis as needed. Follow-up
extended from the baseline exam until the development of
NAFLD or the last health exam conducted for each participant.
The average follow-up period for participants who did not develop
NAFLD was 5.4 years. The cumulative incidence of NAFLD by
quartile of total, indirect and direct bilirubin concentrations was
assessed by Kaplan-Meier plots. We then estimated adjusted
hazard ratios (and 95% confidence intervals) for incident NAFLD
comparing the three highest quartiles of baseline serum bilirubin
to the lowest quartile using proportional hazards regression. Since
we knew that NAFLD had occurred between two visits but did not
know the precise time of NAFLD development, we used a
parametric Cox model to take into account this type of interval
Table 2. Hazard ratios (95% confidence intervals) for incident non-alcoholic fatty liver disease by serum bilirubin quartiles
(N=5,900).
Person-years
No. of incident
cases
Age-adjusted HR
(95% CI) Multivariate HR
* (95% CI)
Model 1 Model 2
Direct bilirubin (mg/dL)
0– 10127.5 841 1.00 (reference) 1.00 (reference) 1.00 (reference)
0.4– 6220.3 433 0.83 (0.73–0.93) 0.87 (0.77–0.98) 0.94 (0.83–1.05)
0.5– 4413.7 286 0.77 (0.67–0.88) 0.86 (0.75–0.98) 0.97 (0.85–1.12)
0.6–1.7 7340.4 378 0.61 (0.54–0.68) 0.73 (0.65–0.83) 0.86 (0.76–0.98)
P for trend ,0.001 ,0.001 0.039
Indirect bilirubin (mg/dL)
0– 7729.9 565 1.00 (reference) 1.00 (reference) 1.00 (reference)
0.6– 8971.7 658 1.00 (0.89–1.12) 0.99 (0.89–1.11) 1.06 (0.95–1.19)
0.7– 5929.4 377 0.87 (0.76–0.99) 0.92 (0.81–1.05) 0.99 (0.87–1.13)
0.9–3.5 5470.8 338 0.84 (0.74–0.97) 0.91 (0. 79–1.04) 0.99 (0.86–1.14)
P for trend 0.003 0.10 0.72
Total bilirubin (mg/dL)
0.3– 9607.7 749 1.00 (reference) 1.00 (reference) 1.00 (reference)
1.0– 5713.5 431 0.96 (0.85–1.08) 0.97 (0.86–1.09) 1.04 (0.92–1.17)
1.2– 6531.6 388 0.75 (0.67–0.85) 0.82 (0.72–0.93) 0.91 (0.80–1.03)
1.5–4.4 6249.0 370 0.76 (0.67–0.86) 0.87 (0.76–0.98) 0.97 (0.85–1.10)
P for trend ,0.001 0.002 0.31
Model 1: Adjusted for age, BMI, current smoking, alcohol intake, exercise, diabetes mellitus, history of cardiovascular disease and history of malignancy.
Model 2: Further adjusted for HDL cholesterol, triglycerides, glucose, insulin, and uric acid.
Abbreviations: BMI, body mass index; CI, confidence intervals; HDL-C, high-density lipoprotein-cholesterol; HR, hazard ratios.
doi:10.1371/journal.pone.0037241.t002
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parameterized with restricted cubic splines in log time with four
degrees of freedom.
Proportional hazards models were initially adjusted for age,
then for body mass index, smoking, alcohol intake, exercise,
diabetes mellitus, history of cardiovascular disease, history of
malignancy, and then for other metabolic markers including
fasting blood glucose, systolic blood pressure, triglycerides, HDL-
cholesterol, HOMA-IR and C reactive protein. For testing linear
risk trends, we used the quartile rank as a continuous variable in
the regression models. We checked the proportional hazards
assumption by examining graphs of estimated log(-log) survival. In
addition, we estimated the hazard ratio for incident NAFLD
associated with an increase in 1 mg/dL of serum bilirubin
modeled as a continuous variable. We further explored the shape
of the dose-response relation between serum bilirubin concentra-
tion and NAFLD incidence by using restricted quadratic splines
with knots at the 5
th,5 0
th, and 95
th percentiles of the bilirubin
distribution. Statistical analyses were performed using Stata
version 11 (StataCorp LP, College Station, TX, USA). All P
values reported were 2-tailed, and statistical significance was set at
P,0.05.
Results
At baseline, the mean (SD) age, body mass index, and serum
total, direct and indirect bilirubin levels of study participants were
36.8 (4.9) years, 22.9 (2.4) kg/m
2, 1.2 (0.5) mg/dL, 0.4 (0.2) mg/
dL, and 0.7 (0.3) mg/dL, respectively (Table 1). The prevalences
of current smoking, hypertension and metabolic syndrome were
43.4, 12.1 and 4.8%, respectively. Serum direct bilirubin levels
were inversely associated with a variety of metabolic parameters,
including body mass index, glucose, total cholesterol, LDL-
cholesterol, triglycerides, liver enzymes, hsCRP, insulin and
HOMA-IR, and positively associated with HDL-cholesterol levels
(Table 1). Serum direct bilirubin levels were also inversely
associated with current smoking and with the prevalence of the
metabolic syndrome. Serum total and indirect bilirubin levels
showed a similar association pattern with demographic, anthro-
mpometric, and cardiometabolic parameters compared to serum
direct bilirubin (Tables S1 and S2), but serum total and indirect
bilirubin levels were positively associated with uric acid while
serum direct bilirubin levels were not. Serum indirect bilirubin
levels were positively associated with blood pressure while total
and direct bilirubin levels were not.
During 28,101.8 person-years of follow-up, 1,938 participants
developed NAFLD (rate 6.9 per 100 person-years). Decreasing
levels of serum direct bilirubin were progressively associated with
increasing incidence of NAFLD (Figure 1 and Table 2). In age-
adjusted models, the hazard ratios for NAFLD comparing
quartiles 2–4 vs. quartile 1 of serum direct bilirubin were 0.83
(95% confidence interval 0.73–0.93), 0.77 (0.67–0.88) and 0.61
(0.54–0.68), respectively. After adjusting for body mass index,
smoking, alcohol intake, exercise, diabetes mellitus, history of
cardiovascular diseae and malignancy, the hazard ratio for
NAFLD in the highest quartile compared to the lowest was 0.73
(0.65–0. 83; P trend,0.001). The association also persisted after
adjusting for multiple metabolic parameters (hazard ratio com-
paring the highest to the lowest quartile 0.86, 95% CI 0.76–0.98; P
trend=0.039). Similar associations were also observed when the
analysis was restricted to participants without metabolic syndrome,
insulin resistance (HOMA2-IR$1.07, highest quartile in the study
population) or obesity (BMI$25 kg/m
2) at baseline (data not
shown). When serum direct bilirubin was introduced as a
continuous variable in multivariate models, the hazard ratio for
NAFLD associated with an increase of 1 mg/dL in direct bilirubin
was 0.77 (95% CI 0.61–0.98; P=0.037). Spline regression analyses
suggested that the association of bilirubin with incident NAFLD
was nonlinear (P-value for non-linear spline terms=0.04), but an
inverse association between bilirubin and NAFLD was still evident
above direct bilirubin concentrations of 0.30 mg/dL, representing
the 25
th percentile of the direct bilirubin distribution (Figure 2).
In both the age-adjusted model and the model further adjusted
for body mass index, smoking, alcohol intake and exercise,
diabetes mellitus, history of cardiovascular diseae and malignancy,
serum total bilirubin levels were inversely associated with a
significantly increased risk for NAFLD (Table 2). This association,
however, did not persist after adjusting for multiple metabolic
parameters. Serum levels of indirect bilirubin were not associated
with incident NAFLD after adjusting for age, BMI, smoking,
alcohol intake, exercise, diabetes mellitus, history of cardiovascular
disease and malignancy (Table 2). After exclusion of participants
(n=134) with elevated GGT of $63 IU/L or elevated alkaline
phosphatase of $130 IU/L (upper reference intervals used at
Kangbuk Samsung Hospital, respectively), the hazard ratio for
NAFLD comparing the highest to the lowest quartile of serum
direct bilirubin levels didn’t change qualitatively (0.84, 95% CI
0.75–0.97). In sensitivity analyses, we repeated the analyses after
including all eligible participants that had liver disease or risk
factors for liver disease at baseline except for NAFLD, with
consistent findings (Tables S3 and S4).
Discussion
In this longitudinal study of Korean healthy men, higher serum
direct bilirubin levels were significantly associated with a lower risk
of developing new cases of NAFLD even after adjusting for
obesity, insulin resistance, and other metabolic parameters.
Neither total nor indirect bilirubin levels were significantly
associated with NAFLD incidence. Our study, the first one to
show an association between serum direct bilirubin and the
development of NAFLD, suggests that prediagnostic levels of
serum bilirubin may play a role in progression to NAFLD and
further contributes to an accumulating body of evidence showing
that increased serum bilirubin levels are inversely associated with
health outcomes related to oxidative stress including coronary
artery disease, peripheral vascular disease and cancer [31,32,33].
Bilirubin has long been considered simply as the metabolic end
product of heme catabolism, but it is becoming increasingly
evident that bilirubin can act as a potent antioxidant under
physiologic conditions [11] and may play an important role in
protecting from oxidative stress [12,34]. In our study, current
smoking was inversely associated with all types of serum bilirubin
concentrations. Cigarette smoke might enhance bilirubin oxida-
tion, resulting in decreased bilirubin concentration [35]. Oxidative
stress seems to be a major contributor to the pathogenesis of
NAFLD [36], even in normal glucose tolerance subjects without
insulin resistance [37]. Indeed, increases in reactive oxygen species
levels may precede the onset of insulin resistance [38] and lead to
diminished insulin action [39], and lipid peroxidation, inflamma-
tion and cellular injury [40]. In addition to oxidative stress,
NAFLD is also related to insulin resistance. While low serum
bilirubin levels are also associated with increased HOMA-IR and
insulin levels [13], the association between increased direct
bilirubin and lower incidence of NAFLD in our study persisted
after adjusting for a variety of measures of insulin resistance and
after restricting the analysis to participants with no evidence of
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bilirubin is independent of insulin resistance.
Bilirubin may also be linked to NAFLD via fatty acid
metabolism. Elevated de novo lipogenesis and peripheral fatty
acids mainly derived from lipolysis of adipose tissue contribute to
the accumulation of hepatic fat in NAFLD [3,41]. Bilirubin
showed antilipolytic activity in animal models [42,43] probably
due to direct inhibition of triglyceride lipase [43]. On the other
hand, serum bilirubin concentrations can influence free fatty acid
metabolism [44]. Furthermore, free fatty acids may interfere with
bilirubin metabolism at any stage, from blood transport to its
conjugation by the hepatocyte [45,46], and the control of serum
bilirubin concentrations may be linked to lipid metabolism [45].
Total bilirubin consists of direct (conjugated) and indirect
(unconjugated) bilirubin. Unconjugated bilirubin is derived from
reduction of biliverdin, a product of heme degradation, by
biliverdin reductase [47]. Unconjugated bilirubin is strongly
bound to serum albumin, which transports it to the liver. In
hepatocytes, bilirubin is conjugated with one or two molecules of
glucuronic acid, a reaction catalyzed by bilirubin-UDP-glucur-
onosyltransferase [48]. In comparion to unconjugated bilirubin,
conjugated bilirubin is soluble in serum and only weakly bound to
albumin, and thus more easily available in active form compared
to indirect bilirubin [49]. While our study found that the inverse
association between bilirubin and incident NAFLD was restricted
to direct bilirubin, most previous studies of bilirubin levels and
cardiometabolic endpoints measured only total bilirubin without
separation of bilirubin types. There is only limited data showing a
differentially protective effect of direct bilirubin on metabolic
syndrome, but fasting direct bilirubin levels were also inversely
associated with the metabolic syndrome [50] and with their
components [51] in Korean men and women.
There are several limitations to our study. First, we used USFL
in participants without other apparent causes of fatty liver disease
as our marker of NAFLD without histologic confirmation for fatty
liver. Although USFL seems to be a reliable marker of biopsy-
detected fatty liver [27,52], measurement error in outcome
assessment in our study may have diluted the observed associa-
tions. Second, total and direct bilirubin were measured a single
time, thus adding further measurement error and potential
attenuation of the associations. Third, alcohol intake, a common
cause of fatty liver in Korean men, was self-reported and was likely
underestimated. However, the relationship between serum direct
bilirubin and incident NAFLD was similar after excluding
participants with serum GGT of $40 U/I (75
th percentile of
GGT in our study population [23]), a commonly used marker of
alcohol consumption. _ENREF_24 Finally, we studied young,
healthy working Korean men, a population with only moderate
prevalence of obesity and insulin resistance but relatively high
prevalence of NAFLD and our findings may not be generalizable
to women or to men in other populations.
Major strengths of our study include the large sample size, its
prospective design, and the availability of detailed health exam
and laboratory information, that allowed us to identify a cohort of
participants with very low probability of traditional liver risk
factors and of liver disease at baseline and to adjust for a variety of
cardiometabolic risk factors. Our understanding of bilirubin
function is expanding rapidly, and several epidemiological studies
have reported potentially protective effects elevated bilirubin
concentrations on diabetes, cardiovascular disease or cancer
[14,15,16,17,18,19,53]. Our study extends the range of health
outcomes inversely associated with bilirubin concentrations and
avoids the limitations of cross-sectional studies.
In conclusion, we found an inverse association between serum
direct bilirubin and the incidence of NAFLD in a cohort of young,
healthy Korean males. The cohort design and the sensitivity
analysis restricting the sample to non-obese patients with no
evidence of insulin resistance further suggest that this association is
independent of other established causes of NAFLD. Our findings
thus suggest that serum direct bilirubin levels may play a role in
preventing NAFLD, but further research is needed to understand
potential protective mechanisms of bilirubin on NAFLD and other
chronic diseases.
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